Biotechnology involves the exploitation of biological processes for industrial and other related purposes. This branch of study is a combination of science and technology and contributes to the advancement in the field of life sciences for creating genetic modifications of living organisms.
A large portion of inventions and advancements (antibodies, GMOs, biomarkers) in biotechnology involve sequencing genes, amino acid and nucleotide bases to transform the genetic make-up to produce modified (enhanced) living organisms.
A gene consists of a chain of polynucleotides consisting of the nucleotide sequences composed of bases – Adenine (A), Thymine (T), Guanine (G) and Cytosine (C) that code for amino acids. These amino acids are the building blocks of proteins and there are 20 naturally occurring amino acids. A special one-letter or triple letter codes represent each amino acid.
➣ Experts with experience in Creating Compliant Sequence Listing
TSLC have a team of biotechnology and biological sciences experts who are conversant with WIPO, USA, and other jurisdictional norms.
All our experts receive extensive training in creating listings that adhere to the latest standards.
The team consults with the client and provides any additional information needed for preparing sequence listing as required by the patent and trademark office (PTO).
We constantly integrate in-house algorithms with tools for preparing sequence listing, such as WIPO Sequence Suite, PatentIn 3.5, and BiSSAP software, to minimize efforts and generate results that are specific to the client.
There are inventions dealing with peptide and/or DNA sequences such as inventions related to biomarkers, Antibodies, Oligonucleotides etc. where there is a requirement to list the DNA/Peptide sequences at the time of filing the patent application.
The sequences provided in the patents are to comply with the PTO filing regulations following the required norms and regulations.
Patent offices require applicants to file sequence listings in a standardized form.
The ST.26 standard requires sequence listings in the XML format for all applications that have a filing date or international filing date on or after July 1, 2022.
Sequence listings in ST.25 format are required for any applications needing it and having a filing date or international filing date prior to July 1, 2022.
Advantages of Sequence Listings
Within a patent document, genetic sequences are viewed both legally and practically as either chemical compounds or as information-encoding elements. Their structure and function holds great importance within the context of patent eligibility or infringement issues.
Sequence listing allows the applicant to create a single listing that is acceptable to all receiving Offices, Preliminary Examining Authorities and International Searching Authorities for international phase purposes, as well as to all designated and elected National Phase Offices.
Sequence listings prepared with strict compliance to US (37 CFR 1.831–1.835) and WIPO standard ST.26 AND US 37 C.F.R. §§ 1.821-1.825 and WIPO standard ST. 25.
WIPO Sequence database is used to prepare ST.26-compliant sequence listings.
PatentIn Version 3.5 software (see MPEP § 2430) and BiSSAP generate sequence listings that meet all of the requirements of WIPO Standard ST.25.
➣ The biological sequences are prepared in all possible formats:
XML 1.0 format, encoded with Unicode UTF-8, and compliant with the WIPO Standard ST.26 Document Type Definition (DTD)
ASCII text (uploaded via Electronic Filing System)